60 Degrees Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 25, 2023 and accepted by EDGAR at Aug 25, 2023, 15:26 ET.
Management's discussion and analysis
As filed, 55,546 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and the other information set forth in the Registration Statement on Form S-1, as amended (File No. 269483) (the “Registration Statement”), initially filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023. In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ significantly from those anticipated in these forward-looking statements as a result of certain factors discussed herein and any other periodic reports filed and to be filed with the SEC.
Overview
We specialize in the cost-effective development and commercialization of small molecule therapeutics for infectious diseases. We have a single FDA-approved product Arakoda, for malaria prevention in travelers. This product is revenue-generating in the United States and foreign markets, but not yet profitable, primarily due to the lack of an active marketing campaign following its introduction into the U.S. supply chain in late 2019. The COVID-19 pandemic curtailed foreign travel and therefore any ability to raise financing to support an active marketing effort.
We believe that the pathway to profitability lies through future investment in an active marketing program and recruitment of a direct sales force to support Arakoda. However, the return on investment for such an effort is likely to be much greater if it can be shown that the pool of potential prescriptions/patients is larger than that for malaria prevention alone. To that end, our primary operational goal is to demonstrate the clinical effectiveness of the already approved dosing regimen of Arakoda in other disease states. Thus, in the second half of 2023, our focus will be on executing a Phase II B clinical investigation of the efficacy of Arakoda in COVID-19 outpatients. Other supporting activities referenced below and elsewhere in this document, such as improving technical specifications, limited marketing efforts, portfolio development, and observing the progress of foreign market growth, will be conducted as resources permit.
Business Developments
The following highlights material business developments in our business during the quarter ended June 30, 2023:
- In June 2023, we announced that positive Phase II study data for ARAKODA® (tafenoquine) in patients with mild-moderate COVID-19 disease was published by New Microbes and New Infections.
- In June 2023, we announced that larger studies are planned to confirm ARAKODA accelerates clinical recovery in mild-moderate COVID-19.
Key Factors Affecting our Performance
As a result of a number of factors, our historical results of operations may not be comparable to our results of operations in future periods, and our results of operations may not be directly comparable from period to period. Set forth below is a brief discussion of the key factors impacting our results of operations.
Known Trends and Uncertainties
Inflation
Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented.
Supply Chain
Our approved product, Arakoda, is manufactured in India. During the COVID-19 pandemic, our contract manufacturer experienced reduced capacity, which in theory, but not in practice, could have disrupted continuity of U.S. supply of Arakoda.
Geopolitical Conditions
In February 2022, Russia initiated significant military action against Ukraine. Russia’s invasion, the responses of countries and political bodies to Russia’s actions, and the potential for wider conflict may increase financial market volatility and could have adverse effects on regional and global economic markets, including the markets for certain securities and commodities. Following Russia’s actions, various countries, including the United States, Canada, the United Kingdom, Germany and France, as well as the European Union, issued broad-ranging economic sanctions against Russia. The sanctions consist of the prohibition of trading in certain Russian securities and engaging in certain private transactions, the prohibition of doing business with certain Russian corporate entities, large financial institutions, officials and persons and the freezing of Russian assets. The sanctions include a possible commitment by certain countries and the European Union to remove selected Russian banks from the Society for Worldwide Interbank Financial Telecommunications, commonly called “SWIFT,” the electronic network that connects banks globally, and imposed restrictive measures to prevent the Russian Central Bank from undermining the impact of the sanctions. A number of large corporations and U.S. states have also announced plans to curtail business dealings with certain Russian businesses.
The imposition of the current sanctions (and potential imposition of further sanctions in response to continued Russian military activity) and other actions undertaken by countries and businesses may adversely impact various sectors of the Russian economy, and the military action has severe impacts on the Ukrainian economy, including its exports and food production. The duration of ongoing hostilities and corresponding sanctions and related events cannot be predicted and may result in a negative impact on the markets and thereby may negatively impact our business, financial condition and results of operation.
Effects of COVID-19
COVID-19 has globally resulted in loss of life, business closures, restrictions on travel, and widespread cancellation of social gatherings. There is considerable uncertainty around the impact of any future outbreaks of COVID-19. Therefore, COVID-19 may negatively impact our operating results.
The extent to which any future COVID-19 outbreaks impact our business will depend on future developments, which are highly uncertain and cannot be predicted at this time, including:
- new information which may emerge concerning the severity of the disease;
- the duration and spread of the outbreak;
- the severity of travel restrictions imposed by geographic areas in which we operate, mandatory or voluntary business closures;
- our ability to enroll patients;
- regulatory actions taken in response to the outbreak, which may impact merchant operations, consumer and merchant pricing, and our product offerings;
- other business disruptions that affect our workforce and supply chain;
- the impact on capital and financial markets; and
- actions taken throughout the world, including in markets in which we operate, to contain the COVID-19 outbreak or treat its impact.
Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding any future outbreak of COVID-19 and the actions taken by government authorities and other entities to contain any future outbreak of COVID-19 or treat its impact, almost all of which are beyond our control. If the disruptions posed by the COVID-19 or other matters of global concern continue for an extensive period of time, the operations of our business may be materially adversely affected.
To the extent the COVID-19 or a similar public health threat has an impact on our business, it is likely to also have the effect of heightening many of the other risks described in the “Risk Factors” section of the Registration Statement.
Seasonality
Our business could be affected by seasonal variations. For instance, we expect to experience higher sales in the second and third quarters of the fiscal year. However, taken as a whole, seasonality does not have a material impact on our financial results.
Foreign Currency
Our reporting currency is the U.S. dollar and our operations in Australia and Singapore use their local currency as their functional currencies. We are subject to the effects of exchange rate fluctuations with respect to any of such currency. The income statements of some of our operations are translated into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens against foreign currencies, the translation of these foreign currencies denominated transactions results in reduced revenue, operating expenses and net income for our international operations. We are also exposed to foreign exchange rate fluctuations as we convert the financial statements of our foreign subsidiaries into U.S. dollars in consolidation.
Components of Results of Operations
Product Revenues – net of Discounts and Rebates
To date, we have received the majority of our product revenues from sales of our Arakoda™ product to the US Department of Defense (the “DoD”) and resellers in the U.S. and abroad. Foreign sales to both Australia and Europe are further subject to profit sharing agreements for boxes sold to customers. Currently, the procurement contract with the DoD has expired and DoD sales last happened in 2021. Sales to resellers in the US are subject to considerable discounts and rebates for services provided by our third-party logistics (“3PL”) partner and wholesalers and pharmacy benefit managers (“PBMs”).
Cost of Revenues, Gross Loss, and Gross Margin
Cost of revenues associated with our products is primarily comprised of direct materials, manufacturing related costs incurred in the production process, royalties due on product sales, inventory write-downs, labor and overhead.
Other Operating Revenues
Our research revenues have historically been derived mostly from a single, awarded research grant in the amount of $4,999,814 at the beginning of December 2020 (with an additional $720,000 awarded February 26, 2021) from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (which may be referred to as “JPEO”) to study Arakoda in mild-to-moderate COVID-19 patients. A majority of the study was completed in 2021 with the planned lab data analysis and the submission of the final study report completed during the first nine months of 2022. Research revenue was recognized when research expenses against the JPEO grant were recognized at the end of each month. Research revenues do not exceed directly related research expenses for a given period as the grant did not include the general and administrative, overhead or profit components.
We also earn research revenues from the Australian Tax Authority for research activities conducted in Australia.
Operating Expenses
Research and Development
Research and development costs for the periods presented primarily consist of contracted R&D services and costs associated with preparation for our upcoming COVID-19 clinical trial. We expense all research and development costs in the period in which they are incurred. Payments made prior to the receipt of goods or services to be used in research and development are recognized as prepaid assets and amortized over the service period, as the services are provided. We have also issued shares of our common stock in exchange for services to be used in our operations.
General and Administrative Expenses
Our general and administrative expenses primarily consist of salaries, advertising and promotion expenses, professional services fees, such as consulting, audit, accounting and legal fees, general corporate costs and allocated costs, including facilities, information technology and amortization of intangibles.
Interest and Other Income (Expense), Net
Interest expense consists of accrued interest on our outstanding debt obligations and related amortization of debt discounts and deferred issuance costs. Components of other expense includes changes in the fair value of financial instruments and other miscellaneous income (expense).
Results of Operations
The following table sets forth our results of operations for the periods presented:
| For the Three Months Ended June 30, 2023 | 2022 | For the Six Months Ended June 30, 2023 | 2022 | |
|---|---|---|---|---|
| Product Revenues – net of Discounts and Rebates | $59,532 | $45,173 | $76,704 | $92,197 |
| Cost of Revenues | 183,977 | 87,120 | 257,097 | 177,254 |
| Gross Loss | (124,445) | (41,947) | (180,393) | (85,057) |
| Research Revenues | 3,116 | (7,740) | 7,408 | 109,407 |
| Net (Loss) Revenue | (121,329) | (49,687) | (172,985) | 24,350 |
| Operating Expenses: | ||||
| Research and Development | 203,872 | 231,394 | 327,866 | 294,451 |
| General and Administrative Expenses | 462,795 | 405,838 | 1,237,809 | 580,530 |
| Total Operating Expenses | 666,667 | 637,232 | 1,565,675 | 874,981 |
| Loss from Operations | (787,996) | (686,919) | (1,738,660) | (850,631) |
| Interest Expense | (1,099,656) | (905,519) | (2,241,085) | (1,667,736) |
| Derivative Expense | (399,725) | (504,613) | (399,725) | (504,613) |
| Change in Fair Value of Derivative Liabilities | 7,968 | (1,001) | 2,834 | (1,001) |
| Loss on Debt Extinguishment | - | - | (839,887) | - |
| Change in Fair Value of Promissory Note | (1,064,849) | - | (725,797) | - |
| Other Income (Expense), net | 730 | (51,714) | 1,321 | (32,982) |
| Total Interest and Other Income (Expense), net | (2,555,532) | (1,462,847) | (4,202,339) | (2,206,332) |
| Loss from Operations before Provision for Income Taxes | (3,343,528) | (2,149,766) | (5,940,999) | (3,056,963) |
| Provision for Income Taxes | 63 | 250 | 126 | 500 |
| Net Loss including Noncontrolling Interest | (3,343,591) | (2,150,016) | (5,941,125) | (3,057,463) |
| Net Gain (Loss) – Noncontrolling Interest | (7,036) | (3,117) | (4,509) | 1,718 |
| Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. | (3,336,555) | (2,146,899) | (5,936,616) | (3,059,181) |
| Comprehensive Loss: | ||||
| Net Loss | (3,343,591) | (2,150,016) | (5,941,125) | (3,057,463) |
| Unrealized Foreign Currency Translation Loss | (374) | (110,989) | (1,664) | (14,433) |
| Total Comprehensive Loss | (3,343,965) | (2,261,005) | (5,942,789) | (3,071,896) |
| Net Gain (Loss) – Noncontrolling Interest | (7,036) | (3,117) | (4,509) | 1,718 |
| Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc. | $(3,336,929) | $(2,257,888) | $(5,938,280) | $(3,073,614) |
30
The following table sets forth our results of operations as a percentage of revenue:
| For the Three Months Ended June 30, 2023 | 2022 | For the Six Months Ended June 30, 2023 | 2022 | |
|---|---|---|---|---|
| Product Revenues – net of Discounts and Rebates | 100.00% | 100.00% | 100.00% | 100.00% |
| Cost of Revenues | 309.04 | 192.86 | 335.18 | 192.26 |
| Gross Loss | (209.04) | (92.86) | (235.18) | (92.26) |
| Research Revenues | 5.23 | (17.13) | 9.66 | 118.67 |
| Net (Loss) Revenue | (203.80) | (109.99) | (225.52) | 26.41 |
| Operating Expenses: | - | |||
| Research and Development | 342.46 | 512.24 | 427.44 | 319.37 |
| General and Administrative Expenses | 777.39 | 898.41 | 1,613.75 | 629.66 |
| Total Operating Expenses | 1,119.85 | 1,410.65 | 2,041.19 | 949.03 |
| - | ||||
| Loss from Operations | (1,323.65) | (1,520.64) | (2,266.71) | (922.62) |
| - | - | - | - | |
| Interest Expense | (1,847.17) | (2,004.56) | (2,921.73) | (1,808.88) |
| Derivative Expense | (671.45) | (1,117.07) | (521.13) | (547.32) |
| Change in Fair Value of Derivative Liabilities | 13.38 | (2.22) | 3.69 | (1.09) |
| Loss on Debt Extinguishment | - | - | (1,094.97) | - |
| Change in Fair Value of Promissory Note | (1,788.70) | - | (946.23) | - |
| Other Income (Expense), net | 1.23 | (114.48) | 1.72 | (35.77) |
| Total Interest and Other Income (Expense), net | (4,292.70) | (3,238.32) | (5,478.64) | (2,393.06) |
| Loss from Operations before Provision for Income Taxes | (5,616.35) | (4,758.96) | (7,745.36) | (3,315.69) |
| Provision for Income Taxes | 0.11 | 0.55 | 0.16 | 0.54 |
| Net Loss including Noncontrolling Interest | (5,616.46) | (4,759.52) | (7,745.52) | (3,316.23) |
| Net Gain (Loss) – Noncontrolling Interest | (11.82) | (6.90) | (5.88) | 1.86 |
| Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. | (5,604.64) | (4,752.62) | (7,739.64) | (3,318.09) |
| - | - | - | - | |
| Comprehensive Loss: | - | - | - | - |
| Net Loss | (5,616.46) | (4,759.52) | (7,745.52) | (3,316.23) |
| Unrealized Foreign Currency Translation Loss | (0.63) | (245.70) | (2.17) | (15.65) |
| Total Comprehensive Loss | (5,617.09) | (5,005.21) | (7,747.69) | (3,331.88) |
| Net Gain (Loss) – Noncontrolling Interest | (11.82) | (6.90) | (5.88) | 1.86 |
| Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc. | (5,605.27)% | (4,998.31)% | (7,741.81)% | (3,333.75)% |
Comparison of the Three Months Ended June 30, 2023, and 2022
Product Revenues – net of Discounts and Rebates, Cost of Revenues, Gross Loss, and Gross Margin
| Consolidated Statements of Operations Data: | Three Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Product Revenues – net of Discounts and Rebates | $59,532 | $45,173 | $14,359 | 31.79% |
| Cost of Revenues | 183,977 | 87,120 | 96,857 | 111.18 |
| Gross Loss | $(124,445) | $(41,947) | $(82,498) | 196.67% |
| Gross Margin % | (209.04)% | (92.86)% |
31
Product Revenues – net of Discounts and Rebates
Our product revenues were $59,532 for the three months ended June 30, 2023, as compared to $45,173 for the three months ended June 30, 2022. For the three months ended June 30, 2023, our U.S. distributor accounted for 100% of our total net product sales (100% for the three months ended June 30, 2022). The increase in net product sales is primarily due to increased sales volume during the period and was partially offset by the reduction of our wholesale acquisition cost of Arakoda™ (16 x 100 mg tablets) from $285 to $235 per box in January 2023, in addition to expiring inventory returns.
We offer discounts and rebates to the civilian U.S. supply chain distribution channel. We record sales when our 3PL partner transfers boxes into their title model. Discounts and rebates are offered to our 3PL partner amounting to 11% along with a fixed monthly fee. The product is then transferred normally to one of the three large U.S. pharmaceutical distributors where rebates range from 10-15%. Lastly, we have relationships with several large pharmacy benefit managers (“PBMs”) that allow patients to purchase Arakoda at a discount. The rebate associated with PBMs ranges from 15% to 39.75% depending on the amount of coverage provided. For the three months ended June 30, 2023, discounts and rebates were $22,151 compared to $11,303 for the three months ended June 30, 2022.
Although, as of the date of these financial statements, we were not in discussions with the DoD about additional future procurement, we anticipate that this will be feasible in the future if one or more of the conditions/events described in this paragraph occur. First, the position of Arakoda in the DoD formulary (Tricare, deployed personnel) needs to be improved from second/third tier to at least equivalency with competing products (as is the case for civilian use as recommended by the CDC). Second, the shelf-life of the existing product requires extension, which is known to be technically possible as the shelf-life of Kodatef in Australia is 48 months, but appropriate data must be generated to meet FDA requirements. Finally, a change in the operational footprint of DoD deployments to areas with higher malaria attack rates (e.g., the Liberia deployment to manage the Ebola outbreak in 2014) may lead to a rapid reassessment by DoD of the position of Arakoda in the formulary (advancement of the last approved prophylactic antimalarial to co-equal standard of care took thirteen years).
Arakoda entered the U.S. civilian supply chain in the third quarter of 2019. For the three months ended June 30, 2022, 134 boxes were sold to pharmacies and dispensaries. Sales increased by 150% to 335 boxes to patients for the three months ended June 30, 2023. This growth in sales volumes may be a combination of both natural organic growth and the reduction in the wholesale acquisition cost effective January 2023.
Kodatef sales to our distributor Biocelect in Australia for the three months ended June 30, 2023 were $0 ($0 for the three months ended June 30, 2022). Sales to Biocelect are currently subject to a profit share distribution once the original transfer price has been recouped. As of June 30, 2023, no profit share has been due to us and also ($0 for the three months ended June 30, 2022).
Cost of Revenues, Gross Loss, and Gross Margin
The cost of goods sold was $183,977 for the three months ended June 30, 2023, as compared to $87,120 for the three months ended June 30, 2022. The increase in cost of goods sold is primarily due to greater destruction of expired inventory and allowance for expiring inventory. The Gross Margin % fell to (209.04)% for the three months ended June 30, 2023 from (92.86)% for the three months ended June 30, 2022. This is due to the current low sales volume and the fixed part of cost of goods. As the sales volume continues to grow the gross margin will improve as the variable cost of goods of each unit sold is substantially less than the sales price.
Other Operating Revenues
| Consolidated Statements of Operations Data: | Three Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Research Revenues | $3,116 | $(7,740) | 10,856 | (140.26)% |
The research revenues earned by us were $3,116 for the three months ended June 30, 2023, as compared to ($7,740) for the three months ended June 30, 2022. Our research revenues for the periods presented consist entirely of research revenues from the Australian Tax Authority for research activities conducted in Australia. We accrue the Australian tax rebate quarterly and the negative revenue represents a downward correction from the previous three periods.
Operating Expenses
| Consolidated Statements of Operations Data: | Three Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Research and Development | $203,872 | $231,394 | $(27,522) | (11.89)% |
| General and Administrative Expenses | 462,795 | 405,838 | 56,957 | 14.03 |
| Total Operating Expenses | $666,667 | $637,232 | $29,435 | 4.62% |
Research and Development
Research and development costs decreased during the three months ended June 30, 2023 when compared to the three months ended June 30, 2022. Research and development costs incurred during the three months ended June 30, 2022 related to our Phase II clinical trial to assess the safety and efficacy of Tafenoquine for the treatment of mild to moderate COVID-19 disease, which was completed in the third quarter of 2022. During the three months ended June 30, 2023, we incurred initiation costs related to our Phase II B clinical trial, which is expected to commence in the second half of 2023. Direct COVID-19-related trial costs are 90% of the costs for the three months ended June 30, 2023 at $182,887 and 70% of the costs for the three months ended June 30, 2022 at $160,884.
General and Administrative Expenses
For the three months ended June 30, 2023, our general and administrative expenses increased by 14.03% or $56,957 from the three months ended June 30, 2022. While the net amounts did not change substantially during the period, we spent substantially less for professional services fees (accounting, audit, and legal fees) at $89,127 (down from $195,284 for the three months ended June 30, 2022). Whereas, during the three months ended June 30, 2023, we incurred $39,061 for promotion expenses, $56,908 for investor outreach expenses, and $54,000 for pharmacovigilance monitoring costs (up from $5,731, $10,000, and $18,000 for the three months ended June 30, 2022, respectively).
Interest and Other Income (Expense), Net
| Consolidated Statements of Operations Data: | Three Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Interest Expense | $(1,099,656) | $(905,519) | $(194,137) | 21.44% |
| Derivative Expense | (399,725) | (504,613) | 104,888 | (20.79) |
| Change in Fair Value of Derivative Liabilities | 7,968 | (1,001) | 8,969 | (896.00) |
| Change in Fair Value of Promissory Note | (1,064,849) | - | (1,064,849) | NA |
| Other Income (Expense), net | 730 | (51,714) | 52,444 | (101.41) |
| Total Interest and Other Income (Expense), net | $(2,555,532) | $(1,462,847) | $(1,092,685) | 74.70% |
Interest Expense
For the three months ended June 30, 2023, we recognized $1,099,656 of interest expense ($905,519 for the three months ended June 30, 2022). The increase is primarily related to growing principal and interest balances with the primary lender Knight as well as amortization of debt discounts and related issuance costs on our outstanding debt balances. Cash paid for interest expense was $2,193 and $731 for the three months ended June 30, 2023 and June 30, 2022, respectively.
Derivative Expense
For the three months ended June 30, 2023, we recognized $399,725 of derivative expense in connection with the raising of $555,000 in net proceeds from our bridge funding in May 2023. We recognized $504,613 of derivative expense during the three months ended June 30, 2022 from the bridge funding raise in May 2022, generating $979,275 in net proceeds. The decrease in derivative expense is related to the initial fair value of the related derivative liabilities in excess of the cash proceeds received.
Change in Fair Value of Derivative Liabilities
For the three months ended June 30, 2023, we recognized a change in fair value of derivative liabilities of $7,968 and ($1,001) for the three months ended June 30, 2022. The increase is related to additional derivatives generated from the bridge funding raise in May 2023.
Change in Fair Value of Promissory Note
For the three months ended June 30, 2023, we recognized a $1,064,849 loss related to the increase in the fair value of the promissory note with Knight (none for the three months ended June 30, 2022). Our cumulative debt outstanding with Knight was not measured at fair value on a recurring basis prior to the Knight Debt Conversion Agreement executed in January 2023, hence we recorded a $0 change in fair value for the three months ended June 30, 2022.
Other Income (Expense), net
For the three months ended June 30, 2023, we recognized $730 in other income compared to $51,714 in other expense for the three months ended June 30, 2022. The decrease is primarily related to a $51,365 loss on disposal of 60P Singapore Pty Lte recognized during the three months ended June 30, 2022.
Comparison of the Six Months Ended June 30, 2023 and 2022
Product Revenues – net of Discounts and Rebates, Cost of Revenues, Gross Loss, and Gross Margin
| Consolidated Statements of Operations Data: | Six Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Product Revenues – net of Discounts and Rebates | $76,704 | $92,197 | $(15,493) | (16.80)% |
| Cost of Revenues | 257,097 | 177,254 | 79,843 | 45.04 |
| Gross Loss | $(180,393) | $(85,057) | $(95,336) | 112.08% |
| Gross Margin % | (235.18)% | (92.26)% |
Product Revenues – net of Discounts and Rebates
Our product revenues were $76,704 for the six months ended June 30, 2023, as compared to $92,197 for the six months ended June 30, 2022. For the six months ended June 30, 2023, our Australian distributor accounted for 71% (0% for the six months ended of June 30, 2022), and our U.S. distributor accounted for 29% of our total net product sales (100% for the six months ended June 30, 2022). While our sales volume increased over the same periods, the decrease in net product sales was impacted by the reduction of our wholesale acquisition cost of Arakoda™ (16 x 100 mg tablets) from $285 to $235 per box in January 2023, in addition to expiring inventory returns.
We offer discounts and rebates to the civilian U.S. supply chain distribution channel. We record sales when our 3PL partner transfers boxes into their title model. Discounts and rebates are offered to our 3PL partner amounting to 11%. The product is then transferred normally to one of the three large U.S. pharmaceutical distributors where rebates range from 10-15%. Lastly, we have relationships with several large pharmacy benefit managers (“PBMs”) that allow patients to purchase Arakoda at a discount. The rebate associated with PBMs ranges from 15% to 39.75% depending on the amount of coverage provided. For the six months ended June 30, 2023, discounts and rebates were $47,649 compared to $24,699 for the six months ended June 30, 2022. This reflects both greater sales volume and the new contract with our 3PL partner at the beginning of 2023 in which both the percentage and fixed fee rebates increased.
Although, as of the date of these financial statements, we were not in discussions with the DoD about additional future procurement, we anticipate that this will be feasible in the future if one or more of the conditions/events described in this paragraph occur. First, the position of Arakoda in the DoD formulary (Tricare, deployed personnel) needs to be improved from second/third tier to at least equivalency with competing products (as is the case for civilian use as recommended by the CDC). Second, the shelf-life of the existing product requires extension, which is known to be technically possible as the shelf-life of Kodatef in Australia is 48 months, but appropriate data must be generated to meet FDA requirements. Finally, a change in the operational footprint of DoD deployments to areas with higher malaria attack rates (e.g., the Liberia deployment to manage the Ebola outbreak in 2014) may lead to a rapid reassessment by DoD of the position of Arakoda in the formulary (advancement of the last approved prophylactic antimalarial to co-equal standard of care took thirteen years).
Arakoda entered the U.S. civilian supply chain in the third quarter of 2019. For the six months ended June 30, 2022, 225 boxes were sold to pharmacies and dispensaries. Sales increased by 129% to 516 boxes to patients for the six months ended June 30, 2023. The increase in commercial sales volume reflects the response to the reduction of our wholesale acquisition cost effective January 2023.
Kodatef sales to our distributor Biocelect in Australia for the six months ended June 30, 2023 were $0 ($0 for the six months ended June 30, 2022). Sales to Biocelect are currently subject to a profit share distribution once the original transfer price has been recouped. As of June 30, 2023, $53,322 was paid ($0 for the six months ended June 30, 2022).
During the first six months of 2023 and 2022, we did not record sales of Arakoda/Kodatef to our European distributor Scandinavian Biopharma Distribution AB. Product will be distributed there on a named patient basis. As in Australia a profit distribution share is possible depending on the retail price established.
Cost of Revenues, Gross Loss, and Gross Margin
The cost of goods sold was $257,097 for the six months ended June 30, 2023, as compared to $177,254 for the six months ended June 30, 2022. The increase in cost of goods sold is primarily due to a greater allowance for expiring inventory. The Gross Margin % fell to (235.18)% for the six months ended June 30, 2023 from (92.26)% for the six months ended June 30, 2022. This is partially due to the current low sales volume and the fixed part of cost of goods. As the sales volume continues to grow the gross margin will improve as the variable cost of goods of each unit sold is substantially less than the sales price. However, right now the allowance required for expiring inventory provides the largest negative impact to Gross Margin.
Other Operating Revenues
| Consolidated Statements of Operations Data: | Six Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Research Revenues | $7,408 | $109,407 | $(101,999) | (93.23)% |
The research revenues earned by us were $7,408 for the six months ended June 30, 2023, as compared to $109,407 for the six months ended June 30, 2022. Our research revenues have historically been derived mostly from a single, awarded research grant in the amount of $4,999,814 at the beginning of December 2020 (with an additional $720,000 awarded in February of 2021) from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (which may be referred to as “JPEO”) to study Arakoda in mild-to-moderate COVID-19 patients. A majority of the study was completed in 2021 with the planned lab data analysis and the submission of the final study report completed during the first nine months of 2022. During the six months ended June 30, 2022, we recognized $94,908 in revenue from the JPEO, compared to $0 during the six months ended June 30, 2023. We also earn research revenues from the Australian Tax Authority for research activities conducted in Australia. The revenue was $7,408 for the six months ended June 30, 2023 compared to $14,499 during the six months ended June 30, 2022.
Operating Expenses
| Consolidated Statements of Operations Data: | Six Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Research and Development | $327,866 | $294,451 | $33,415 | 11.35% |
| General and Administrative Expenses | 1,237,809 | 580,530 | 657,279 | 113.22 |
| Total Operating Expenses | $1,565,675 | $874,981 | $690,694 | 78.94% |
Research and Development
Research and development costs increased during the six months ended June 30, 2023 when compared to the six months ended June 30, 2022. Research and development costs incurred during the six months ended June 30, 2022 related to our Phase II clinical trial to assess the safety and efficacy of Tafenoquine for the treatment of mild to moderate COVID-19 disease, which was completed in the third quarter of 2022. During the six months ended June 30, 2023, we incurred initiation costs related to our Phase II B clinical trial, which is expected to commence in the second half of 2023. Direct COVID-19-related trial costs are 88% of the costs for the six months ended June 30, 2023 at $288,144 and 61% of the costs for the six months ended June 30, 2022 at $180,484.
General and Administrative Expenses
For the six months ended June 30, 2023, our general and administrative expenses increased by 113.22% or $657,279 over the six months ended June 30, 2022. During the six months ended June 30, 2023 we spent substantially more for accounting and auditing at $450,843 (up from $59,439 for the six months ended June 30, 2022). Additionally, during the six months ended June 30, 2023, we incurred $221,447 of investor outreach expenses, $75,665 of advertising and promotion expenses, and $144,000 of pharmacovigilance monitoring costs (up from $10,000, $5,731, and $30,000 for the six months ended June 30, 2022, respectively).
Interest and Other Income (Expense), Net
| Consolidated Statements of Operations Data: | Six Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Interest Expense | $(2,241,085) | $(1,667,736) | $(573,349) | 34.38% |
| Derivative Expense | (399,725) | (504,613) | 104,888 | (20.79) |
| Change in Fair Value of Derivative Liabilities | 2,834 | (1,001) | 3,835 | (383.12) |
| Loss on Debt Extinguishment | (839,887) | - | (839,887) | NA |
| Change in Fair Value of Promissory Note | (725,797) | - | (725,797) | NA |
| Other Income (Expense), net | 1,321 | (32,982) | 34,303 | (104.01) |
| Total Interest and Other Income (Expense), net | $(4,202,339) | $(2,206,332) | $(1,996,007) | 90.47% |
Interest Expense
For the six months ended June 30, 2023, we recognized $2,241,085 of interest expense ($1,667,736 for the six months ended June 30, 2022). The increase is primarily related to growing principal and interest balances with the primary lender Knight, as well as amortization of debt discounts and related issuance costs on our outstanding debt balances. Cash paid for interest expense was $4,386 and $731 for the six months ended June 30, 2023 and June 30, 2022, respectively.
Derivative Expense
For the six months ended June 30, 2023, we recognized $399,725 of derivative expense in connection with the raising of $555,000 in net proceeds from our bridge funding in May 2023. We recognized $504,613 of derivative expense during the six months ended June 30, 2022 from the bridge funding raise in May 2022, generating $979,275 in net proceeds. The decrease in derivative expense is related to the initial fair value of the related derivative liabilities in excess of the cash proceeds received.
Change in Fair Value of Derivative Liabilities
For the six months ended June 30, 2023, we recognized a change in fair value of derivative liabilities of $2,834 and ($1,001) for the six months ended June 30, 2022.
Loss on Debt Extinguishment
For the six months ended June 30, 2023, we recognized a $839,887 loss on debt extinguishment (none for the six months ended June 30, 2022). The increase in loss is related to the conversion of the cumulative outstanding debt pursuant to the Knight Debt Conversion Agreement in January 2023.
Change in Fair Value of Promissory Note
For the six months ended June 30, 2023, we recognized a $725,797 loss related to the increase in the fair value of the promissory note with Knight (none for the six months ended June 30, 2022). Our cumulative debt outstanding with Knight was not measured at fair value on a recurring basis prior to the Knight Debt Conversion Agreement executed in January 2023, hence we recorded a $0 change in fair value for the six months ended June 30, 2022.
Other Income (Expense), net
For the six months ended June 30, 2023, we recognized $1,321 in other income compared to $32,982 in other expense for the six months ended June 30, 2022. In 2022, it was uncovered that federal tax form 8992 may have not been properly filed. We elected to record a $30,000 tax liability during the six months ended June 30, 2022, $10,000 each for the audits of the years ended December 31, 2019, 2020 and 2021.
Liquidity and Capital Resources
For the six months ended June 30, 2023 and 2022, our net cash used in operating activities was $726,168 and $636,944, respectively and the cash balance was $19,070 as of June 30, 2023 ($264,865 as of December 31, 2022). Based on current internal projections, given funds received from the initial public offering (“IPO”) and warrant exercise, and if our planned COVID-19 clinical study is eligible to receive Australian government research and development tax rebates and it is possible to borrow and receive funds from a lender ahead of issuance of those tax rebates, we estimate that we will have sufficient funds to remain viable through March 31, 2024 (sufficient to complete an optional futility analysis at 33% enrolment in the clinical study if desired). However, we may not remain viable until March 31, 2024, if we end up being ineligible for research tax credits or cannot borrow against their future issuance. We cannot give assurance that we can increase our cash balances or limit our cash consumption and thus maintain sufficient cash balances for our planned operations or future acquisitions. Future business demands may lead to cash utilization at levels greater than recently experienced. We may need to raise additional capital in the future. However, we cannot assure you that we will be able to raise additional capital on acceptable terms, or at all.
To date, we have funded our operations through debt and equity financings.
Going Concern
As of June 30, 2023, we had an accumulated deficit of $34,791,255. In their audit report for the fiscal year ended December 31, 2022, our auditors have expressed their concern as to our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to generate cashflows from operations and obtain financing.
The consolidated financial statements for the twelve months ended December 31, 2022, and December 31, 2021, respectively, included an explanatory note referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. The accompanying consolidated condensed financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. To date, we have not yet established an ongoing source of revenues and cash flows sufficient to cover our operating costs and allow us to continue as a going concern. These factors among others raise substantial doubt about our ability to continue as a going concern for at least one year from the date of issuance of the accompanying consolidated condensed financial statements.
Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.
Contractual Obligations
The following table summarizes our contractual obligations as of June 30, 2023:
| Total | Payments Due By Period Less than 1 year | 1-3 years | 4-5 years | More than 5 Years | |
|---|---|---|---|---|---|
| Principal obligations on the debt arrangements | $28,656,775 | $27,286,620 | $1,220,155 | $4,456 | $145,544 |
| Interest obligations on the debt arrangements | 186,021 | 183,427 | 2,594 | - | - |
| Operating leases | 39,470 | 39,470 | - | - | - |
| Purchase obligations | 1,353,321 | 1,353,321 | - | ||
| Total | $30,235,587 | $28,862,838 | $1,222,749 | $4,456 | $145,544 |
Cash Flows
The following table sets forth the primary sources and uses of cash for each of the periods presented below:
| Net Cash (Used In) Provided By: | Six Months Ended June 30, 2023 | 2022 | $ Change | % Change |
|---|---|---|---|---|
| Operating Activities | $(726,168) | $(636,944) | $(89,224) | 14.01% |
| Investing Activities | (21,419) | (2,907) | (18,512) | 636.81 |
| Financing Activities | 503,456 | 1,290,335 | (786,879) | (60.98) |
| Effect of Foreign Currency Translation on Cash Flow | (1,664) | (14,433) | 12,769 | (88.47) |
| Net Increase (Decrease) in Cash | $(245,795) | $636,051 | $(881,846) | (138.64)% |
Cash Used in Operating Activities
Net cash used in operating activities was $726,168 for the six months ended June 30, 2023, as compared to $636,944 for the six months ended June 30, 2022. Although our net loss increased approximately 95% over the same periods, (from $3,073,614 for the six months ended June 30, 2022 to $5,980,616 for the six months ended June 30, 2023), our net cash used in operating activities did not change substantially as a result of non-cash expenses impacting net loss, including amortization of capitalized services of $534,408, stock-based compensation expense of $277,605, and a loss on debt extinguishment of $839,887 recognized during the six months ended June 30, 2023 ($0, $0, and $0 for the six months ended June 30, 2022, respectively). In addition, during the six months ended June 30, 2022, we received $94,908 from the JPEO research grant, compared to $0 during the six months ended June 30, 2023.
Cash Used in Investing Activities
Net cash used in investing activities was $21,419 for the six months ended June 30, 2023, as compared to $2,907 for the six months ended June 30, 2022. The increase in net cash used in investing activities was due to higher costs paid for the acquisition of patents as well as capitalized website development costs, which increased from $2,907 and $0 to $15,419 and $39,895, respectively.
Cash Provided by Financing Activities
Net cash provided by financing activities was $503,456 for the six months ended June 30, 2023, as compared to $1,290,335 for the six months ended June 30, 2022. The decrease in net cash provided by financing activities was primarily due to $1,105,000 in bridge round financing received on May 24, 2022, which exceeded the gross cash value raised from the bridge financing on May 8, 2023 of $650,000. In addition, we paid deferred offering costs of ($146,544) during the six months ended June 30, 2023 compared to $0 for the six months ended June 30, 2022.
Effect of Foreign Currency Translation on Cash Flow
Our foreign operations were small relative to U.S. operations for the six months ended June 30, 2023 and June 30, 2022, thus effects of foreign currency translation have been minor.
Critical Accounting Policies, Significant Judgments, and Use of Estimates
The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition
We receive revenues from sales of our Arakoda product to the DoD and resellers in the U.S. and abroad. We record deferred revenues for any advances and then recognize revenue upon shipment to the retailer who orders product for a specific customer. We record a receivable for any amounts to be received pursuant to such sales.
Derivative Liabilities
We assessed the classification of our derivative financial instruments as of June 30, 2023 and December 31, 2022, which consist of bridge shares, convertible notes payable and certain warrants (excluding those for compensation) and have determined that such instruments qualify for treatment as derivative liabilities as they meet the criteria for liability classification under ASC 815.
We analyze all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, “Distinguishing Liabilities from Equity” and FASB ASC Topic No. 815, (“ASC 815”) “Derivatives and Hedging.” Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. We use a Monte Carlo Simulation Model to determine the fair value of these instruments.
Upon conversion or repayment of a debt or equity instrument in exchange for shares of common stock, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), we record the shares of common stock at fair value, relieve all related debt, derivative liabilities, and debt discounts, and recognize a net gain or loss on debt extinguishment. In connection with the debt extinguishment, we typically record an increase to additional paid-in capital for any remaining liability balance.
Equity instruments that are initially classified as equity that become subject to reclassification under ASC 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date.
Original Issue Discount
For certain notes issued, we may provide the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of the note, and is amortized to interest expense over the life of the debt in the Consolidated Statements of Operations and Comprehensive Loss.
Debt Issuance Cost
Debt issuance costs paid to lenders or third parties are recorded as debt discounts and amortized to interest expense over the life of the underlying debt instrument in the Consolidated Statements of Operations and Comprehensive Loss, with the exception of certain debt for which we elected the fair value option.
Income Taxes
From January 1, 2022 to May 31, 2022, 60 Degrees Pharmaceuticals, LLC was a C-corporation for income tax purposes before the incorporation/merger into 60 Degrees Pharmaceuticals, Inc. on June 1, 2022. We account for income taxes under the liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided on deferred tax assets if it is determined that it is more likely than not that the deferred tax asset will not be realized in the following five years. We did not realize any benefits in the year ended December 31, 2022. Most of the deferred tax benefits are abroad and we do not project a profit in our subsidiary by 2026. We record interest, net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense.
We record tax positions taken or expected to be taken in a tax return based upon the amount that is more likely than not to be realized or paid, including in connection with the resolution of any related appeals or other legal processes. Accordingly, we recognize liabilities for certain unrecognized tax benefits based on the amounts that are more likely than not to be settled with the relevant taxing authority. We recognize interest and/or penalties related to unrecognized tax benefits as a component of income tax expense.
Off-Balance Sheet Arrangements
During 2023 and 2022, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
JOBS Act Accounting Election
In April 2012, the JOBS Act was enacted. Section 107(b) of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
Recent Accounting Pronouncements
The Financial Accounting Standards Board (the “FASB”) issues Accounting Standards Update (“ASUs”) to amend the authoritative literature in ASC. There have been a number of ASUs to date, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our consolidated financial statements.
In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with our current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year.
We adopted this pronouncement on January 1, 2022; however, the adoption of this standard did not have a material effect on our consolidated financial statements.
In May 2021, the FASB issued ASUs 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The adoption of this standard in 2022 did not have a material effect on our financial statements.
In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification Topic 606. ASU 2021-08 is effective for fiscal years beginning after December 15, 2022, and early adoption is permitted. The adoption of ASU 2021-08 did not have an effect on our financial statements.
Market risk
As filed, 253 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item.
Controls and procedures
As filed, 2,176 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled “Internal Control—Integrated Framework (2013)” published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on that assessment, our management has identified certain material weaknesses in our internal control over financial reporting.
Our management concluded that as of June 30, 2023, our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas as of June 30, 2023:
(1) we do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;
(2) we have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process, transaction or account changes, and the performance of account reconciliations and approval; and
(3) we have ineffective controls over the period end financial disclosure and reporting process caused by insufficient accounting staff.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 410 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and in item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item. In any event, there have been no material changes in our risk factors as previously disclosed in the Registration Statement.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $59.5k | us-gaap:Revenues |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $76.7k | us-gaap:Revenues |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $184.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $257.1k | us-gaap:CostOfRevenue |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $203.9k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $327.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$788.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $1.1m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $2.2m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $63 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $126 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$3.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$5.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$1.40 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$2.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$1.40 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$2.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 2,378,009 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 2,341,274 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$726.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-06-30 | $19.1k | us-gaap:Cash |
| Current assets | At period end2023-06-30 | $5.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $7.4m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $28.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $30.2m | us-gaap:Liabilities |
| Long-term debt | At period end2023-06-30 | $24.6m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2023-06-30 | −$22.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-23-070884. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.